Contribution: Industrial Research Assistance Program – Contributions to Firms
ImmunoVaccine Technologies Inc.
$636,596.00
Covid-19 Response: DPX-COVID-19: Neutralizing-epitope Based Synthetic Vaccine with Potential for Large Scale Production
FY 2020-21 · 2020-04-01
Summary
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Dartmouth|Dartmouth, Nova Scotia, Canada
Recipient Type
For-profit organization
Business Number
864736772
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2020-04-01 | 2020-21 | $378,239.00 |
| 1 | 2020-04-01 | 2020-21 | $636,596.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days. The total amended value is 258,357 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 61 jours. La valeur totale des modifications est de 258 357 dollars.
Agreement End Date
2020-12-31
Agreement Number
948901
Agreement Start Date
2020-04-01
Agreement Title
Covid-19 Response: DPX-COVID-19: Neutralizing-epitope Based Synthetic Vaccine with Potential for Large Scale Production
Agreement Title (French)
Réponse à la Covid-19 : DPX-COVID-19 : Vaccin synthétique à base d'épitope neutralisant avec un potentiel de production à grande échelle
Agreement Type
Contribution
Agreement Value
$636,596.00
Amendment Date
2020-07-28
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project aims to establish the clinical safety and immunogenicity of a vaccine candidate based on the Company’s DPX delivery technology and incorporating peptides targeting novel epitopes from the coronavirus strain. IMV believes that this peptide-based approach, combined with the portability of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine.
Description (French)
Ce projet vise à établir la sécurité clinique et l'immunogénicité d'un candidat vaccin basé sur la technologie d'administration DPX de l'entreprise et incorporant des peptides ciblant de nouveaux épitopes de la souche coronavirus. IMV estime que cette approche basée sur les peptides, combinée à la portabilité de la plate-forme DPX, offre la possibilité d'accélérer le développement et la production rapide et à grande échelle d'un vaccin.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Dartmouth--Cole Harbour
Federal Riding (French)
Dartmouth--Cole Harbour
Federal Riding Number
12004
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
864736772
Recipient City
Dartmouth|Dartmouth
Recipient Country
CA
Recipient Legal Name
ImmunoVaccine Technologies Inc.
Recipient Postal Code
B3B 2C4
Recipient Province or Territory
NS
Recipient Type
F
Reference Number
172-2020-2021-Q1-948901
